Controlling Gene Activity Reveals New Insights into Immune Cell Behavior

Genes govern cellular functions by being selectively turned on or off through molecular “switches.” These switches, however, can sometimes be improperly activated, causing abnormal cell behavior linked to diseases such as cancer and autoimmune disorders. The activity of these switches is influenced by DNA methylation, chemical marks that can be added or removed to regulate gene expression. 

A research team led by José Luis Sardina at the Josep Carreras Institute has utilized CRISPR-Cas9 technology to precisely control the switch of the IL1RN gene in human leukemia-derived cells by manipulating their methylation status. Their study, conducted with Gemma Valcárcel and Esteban Ballestar’s teams, was published in Science Advances.

This research shows how controlling IL1RN gene activity changes the production of inflammatory cells, which respond abnormally to external triggers. Such altered responses cause these cells to produce modified inflammatory cytokines, which influence tumor growth in laboratory models. The study serves as proof that regulating DNA methylation on key immune genes, like IL1RN, can modulate important functions such as inflammation and tumor progression.

While the connection between chemical DNA modifications and immune behavior was previously suspected, this work provides the first experimental confirmation with clear functional consequences. With the ability to switch individual genes on or off accurately, this research opens pathways for developing novel strategies targeting immune cell biology and suggests potential new therapies for certain leukemia subtypes and diseases involving inflammation.